Ropinirole - Dopamine Agonist for Parkinson's Disease

Ropinirole (Requip, Requip XL)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ropinirole - Dopamine Agonist for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Dopamine Agonist</td>
</tr>
<tr>
<td class="label">Approval Status</td>
<td>FDA Approved (1998)</td>
</tr>
<tr>
<td class="label">Brand Names</td>
<td>Requip, Requip XL, Ropinirole Hydrochloride</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>D2/D3 receptor agonist</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral (immediate and extended-release)</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>6 hours</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>~50%</td>
</tr>
<tr>
<td class="label">Protein Binding</td>
<td>~10-40%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Hepatic (CYP1A2, CYP3A4)</td>
</tr>
<tr>
<td class="label">Elimination</td>
<td>Renal (~90%)</td>
</tr>
<tr>
<td class="label">Time to Peak</td>
<td>1-2 hours</td>
</tr>
<tr>
<td class="label">Interacting Drug</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Ciprofloxacin</td>
<td>Increased ropinirole levels</td>
</tr>
<tr>
<td class="label">Estrogens</td>
<td>May increase levels</td>
</tr>
<tr>
<td class="label">Antipsychotics</td>

...

Ropinirole (Requip, Requip XL)

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Ropinirole - Dopamine Agonist for Parkinson's Disease</th>
</tr>
<tr>
<td class="label">Drug Class</td>
<td>Dopamine Agonist</td>
</tr>
<tr>
<td class="label">Approval Status</td>
<td>FDA Approved (1998)</td>
</tr>
<tr>
<td class="label">Brand Names</td>
<td>Requip, Requip XL, Ropinirole Hydrochloride</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>D2/D3 receptor agonist</td>
</tr>
<tr>
<td class="label">Route of Administration</td>
<td>Oral (immediate and extended-release)</td>
</tr>
<tr>
<td class="label">Half-life</td>
<td>6 hours</td>
</tr>
<tr>
<td class="label">Parameter</td>
<td>Value</td>
</tr>
<tr>
<td class="label">Bioavailability</td>
<td>~50%</td>
</tr>
<tr>
<td class="label">Protein Binding</td>
<td>~10-40%</td>
</tr>
<tr>
<td class="label">Metabolism</td>
<td>Hepatic (CYP1A2, CYP3A4)</td>
</tr>
<tr>
<td class="label">Elimination</td>
<td>Renal (~90%)</td>
</tr>
<tr>
<td class="label">Time to Peak</td>
<td>1-2 hours</td>
</tr>
<tr>
<td class="label">Interacting Drug</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Ciprofloxacin</td>
<td>Increased ropinirole levels</td>
</tr>
<tr>
<td class="label">Estrogens</td>
<td>May increase levels</td>
</tr>
<tr>
<td class="label">Antipsychotics</td>
<td>May reduce dopamine agonist effect</td>
</tr>
<tr>
<td class="label">Metoclopramide</td>
<td>Antagonistic effect</td>
</tr>
</table>

Introduction

Overview

Ropinirole is a non-ergot dopamine agonist used for the treatment of Parkinson's disease and Restless Legs Syndrome (RLS). It provides dopaminergic stimulation by selectively binding to D2 and D3 receptors with minimal activity at other receptor subtypes. [@adler1997]

Mechanism of Action

Ropinirole exerts its therapeutic effects through:

Dopamine Receptor Agonism: Selective D2 and D3 receptor activation

Motor Circuit Normalization: Restores proper basal ganglia signaling

D3 Receptor Affinity: May contribute to mood and motivation effects

Neuroprotective Potential: In vitro studies suggest anti-apoptotic effects

Peripheral D2 Effects: May cause nausea through gut receptors

Clinical Applications

Parkinson's Disease

• Early Monotherapy: First-line for initial symptomatic control
• Adjunct to Levodopa: Reduces motor fluctuations in advanced PD
• Motor Symptom Relief: Effective for tremor, bradykinesia, rigidity
• Extended-Release Form: Once-daily dosing improves compliance

Restless Legs Syndrome

• First-Line Treatment: FDA-approved for moderate-severe primary RLS
• Symptom Reduction: Decreases uncomfortable sensations
• Sleep Quality Improvement: Reduces nighttime awakenings

Off-Label Uses

• Attention-Deficit Hyperactivity Disorder (ADHD)
• Huntington's disease chorea

Pharmacokinetics

Side Effects

Common Side Effects

• Nausea (most common)
• Somnolence, fatigue
• Headache
• Dizziness
• Orthostatic hypotension
• Constipation

Psychiatric Effects

• Hallucinations
• Impulse Control Disorders:
• Pathological gambling
• Compulsive behaviors
• Confusion

Serious Side Effects

• Sudden sleep attacks
• Psychosis
• Syncope
• Cardiac events (rare)

Drug Interactions

Clinical Trials

KEY TRILS

Adler et al. (1998): Ropinirole monotherapy in early PD

The Ropinirole Study Group: Adjunct therapy efficacy

Rascol et al.: Ropinirole extended-release in early PD

Therapeutic Considerations

Advantages

• Non-ergot structure (favorable safety profile)
• Once-daily extended-release option
• Effective for both PD and RLS
• Flexible titration schedule
• Lower impulse control disorder rate than pramipexole (some studies)

Limitations

• Requires three-times-daily dosing (immediate-release)
• Nausea often limits initial titration
• Sleep attacks possible
• Impulse control disorders
• Requires dose escalation over weeks

Research Directions

• Transdermal Delivery: Improving convenience
• Combination Therapy: Studies with MAO-B inhibitors
• Cognitive Effects: Investigating mood benefits
• Biomarkers: Predicting treatment response

See Also

• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Restless Legs Syndrome](/diseases/restless-legs-syndrome)
• [Dopamine Agonists](/therapeutics/dopamine-agonists)
• [Pramipexole](/therapeutics/pramipexole)
• [Rotigotine](/therapeutics/rotigotine)
• [Levodopa](/therapeutics/levodopa)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [ClinicalTrials.gov](https://clinicaltrials.gov/)

Background

The study of Ropinirole Dopamine Agonist For Parkinson'S Disease has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

Mechanism of Action

References

[Adler CH, et al, "Ropinirole for the treatment of early Parkinson's disease." Neurology (1997)](https://pubmed.ncbi.nlm.nih.gov/9270573/)

[Brooks DJ, et al, "Ropinirole in the symptomatic treatment of Parkinson's disease." J Neurol Neurosurg Psychiatry (2000)](https://pubmed.ncbi.nlm.nih.gov/11032621/)

[Pahwa R, et al, "Ropinirole hydrochloride for the treatment of Restless Legs Syndrome." Expert Opin Pharmacother (2006)](https://pubmed.ncbi.nlm.nih.gov/16513380/)

[Hauser RA, et al, "Long-term outcome of ropinirole treatment in Parkinson disease." Clin Neuropharmacol (2006)](https://pubmed.ncbi.nlm.nih.gov/17044293/)

[Antonini A, et al, "Ropinirole for the treatment of Parkinson's disease." Expert Opin Drug Metab Toxicol (2010)](https://pubmed.ncbi.nlm.nih.gov/20629554/)

[Kurlan R, "Ropinirole for Restless Legs Syndrome." N Engl J Med (2005)](https://pubmed.ncbi.nlm.nih.gov/15987920/)

[Stowe R, et al, "Ropinirole for the treatment of Parkinson's disease." Cochrane Database Syst Rev (2008)](https://pubmed.ncbi.nlm.nih.gov/18425901/)

[Trenkwalder C, et al, "Efficacy of ropinirole in Restless Legs Syndrome." Mov Disord (2004)](https://pubmed.ncbi.nlm.nih.gov/15372646/)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [Purinergic P2Y12 Inverse Agonist Therapy](/hypothesis/h-f99ce4ca) — <span style="color:#81c784;font-weight:600">0.71</span> · Target: P2RY12
• [Bacterial Enzyme-Mediated Dopamine Precursor Synthesis](/hypothesis/h-7bb47d7a) — <span style="color:#ffd54f;font-weight:600">0.44</span> · Target: TH, AADC

Related Analyses:

• [What are the mechanisms by which gut microbiome dysbiosis influences Parkinson&#x27;s disease pathogenesi](/analysis/SDA-2026-04-01-gap-20260401-225155) &#x1f504;
• [Synaptic pruning by microglia in early AD](/analysis/SDA-2026-04-01-gap-v2-691b42f1) &#x1f504;